P78.14 The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan

Immune-checkpoint inhibitors (ICI) can be beneficial for treating postoperative recurrence of non-small cell lung cancer (NSCLC) because they provide companion diagnosis and assess the tumor microenvironment on a large amount of cancerous tissue. The treatment efficacy and immune-related adverse effects (irAEs) of postoperative ICIs are poorly reported. Therefore, we aimed to assess the safety and efficacy of ICIs in treating postoperative NSCLC recurrence using irAEs as a measurement.